| 发明名称 |
Treatment of MeCP-2 Associated Disorders |
| 摘要 |
The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome. |
| 申请公布号 |
US2015265554(A1) |
申请公布日期 |
2015.09.24 |
| 申请号 |
US201514733621 |
申请日期 |
2015.06.08 |
| 申请人 |
UNIVERSITÉ D'AIX-MARSEILLE ;INSERM (Institut National de la Santé et de la Recherche Médicale) ;Centre National de la Recherche Scientifique ;INSTITUT CURIE |
发明人 |
Roux Jean-Christophe;Villard Laurent;Saudou Frédérie |
| 分类号 |
A61K31/145;A61K38/13;A61K31/436 |
主分类号 |
A61K31/145 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating a neurological and/or neurodevelopmental disorder that is caused by MeCP2 expression defects in a patient comprising administering to said patient cystamine or cysteamine, or a salt thereof in an amount effective to treat an MECP2-associated disorder. |
| 地址 |
Marseille FR |
